Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.3852W HIGH $30.61
Volume
1.46 M
Value Traded
27.02 M
Short % Float
23.39%
Days to Cover
10.1
+8.58%Week
-1.64%1 Month
+26.79%3 Month
+92.21%6 Month
-72.6%5 Year
+90.08%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.87 B
EPS (TTM)
-2.20
P/E Ratio
-
Ent. Value
1.46 B
Total Shares
74.34 M
Float Shares
69.99 M
Insiders
5.87%
Institutions
109.37%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
XNCR Catalyst Timeline
Dated clinical, regulatory and corporate events for Xencor, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Xencor, Inc.
533Total events
15Upcoming
123Tier-1 (high impact)
2013 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationXmAb819Presentation
XmAb819 Phase 1 dose expansion results presented in proffered paper oral presentation at ESMO 2026
advanced clear cell renal cell carcinomasource ↗
▲Dose Finding UpdateXmAb819Trial
400 mcg/kg selected as proposed IV recommended Phase 3 dose for XmAb819
advanced clear cell renal cell carcinomasource ↗
▲Additional DataXmAb819Clinical Data
October 1, 2026 data cut: 45.5% cORR, 55% uORR, 82% 6-month PFS estimate at 400 mcg/kg
advanced clear cell renal cell carcinomasource ↗
●Enrollment UpdateXmAb819Trial
Phase 1 study enrolled 119 patients with advanced ccRCC across 11 IV dose levels as of September 1, 2026 data cut
advanced clear cell renal cell carcinomasource ↗
▲Pooled AnalysisXmAb819Clinical Data
Pooled analysis: 45% cORR in post PD-(L)1 and ≥2 VEGFR TKI subset; 35% cORR in triple class exposed subset
advanced clear cell renal cell carcinomasource ↗
▲Safety Data UpdateXmAb819Clinical Data
XmAb819 generally well tolerated with 5.9% treatment discontinuation due to related TEAEs
advanced clear cell renal cell carcinomasource ↗
▲License DisputeUltomirisIP / Competition
Settlement agreement with Alexion to resolve U.S. royalty dispute
▲First Patient DosedXmAb412Trial
First-in-human study of XmAb412 expected to begin enrollment
autoimmune and inflammatory diseasessource ↗
●Enrollment UpdateXmAb819Trial
XmAb819 sub-study in intermediate-/poor-risk advanced ccRCC after nivolumab+ipilimumab opened to enrollment
intermediate- or poor-risk advanced ccRCC post IO doublet therapysource ↗
●Poster PresentationXmAb412Presentation
Preclinical characterization of XmAb412 presented at DDW
inflammatory bowel diseasesource ↗
▲Poster PresentationXmAb942Presentation
Final Phase 1 results of XmAb942 presented at DDW
inflammatory bowel diseasesource ↗
◆Oral PresentationXmAb942Presentation
Present final Phase 1 healthy volunteer data at DDW 2026
IBDsource ↗
◆Oral PresentationXmAb819Presentation
XmAb819 dose-expansion data to be presented at medical meeting in 2H26
clear cell renal cell carcinomasource ↗
◆Trial InitiationXmAb412Trial
First-in-human study of XmAb412 to begin in 2H26
inflammatory bowel diseasesource ↗
◆Oral PresentationXmAb541Presentation
Present new clinical data to support a recommended Phase 3 dose
advanced gynecologic and germ cell tumorssource ↗
◆Quarterly UpdatePlamotamabCorporate
Provide an update on progress achieved in the Phase 1b study of plamotamab in RA
rheumatoid arthritis (RA)source ↗
◆Quarterly UpdateXmAb657Corporate
Provide an update on progress achieved in the Phase 1 study of XmAb657 in IIM
idiopathic inflammatory myopathies (IIM)source ↗
▲First Patient DosedXmAb412Trial
Initiate a first-in-human study of XmAb412
inflammatory bowel diseasesource ↗
●Enrollment UpdateXmAb819Trial
XmAb819 sub-study in ENPP3+ advanced CRC, NSCLC and papillary RCC opened to enrollment
ENPP3+ advanced colorectal cancer, non-small cell lung cancer and papillary renal cell carcinomasource ↗
◆Oral PresentationPresentation
Xencor management to present at Leerink Partners Global Healthcare Conference 2026
▼Quarterly UpdateCorporate
Alexion disputes US royalty payments for Ultomiris; Xencor adjusts cash guidance
▲Patent GrantedIP / Competition
Issuance of U.S. Patent 12,492,253 related to Ultomiris royalties
◆Oral PresentationPresentation
Xencor management to present at TD Cowen 46th Annual Health Care Conference
▲Enrollment UpdateXmAb819Trial
XmAb819 dose expansion in CRC, NSCLC and pRCC open to enrollment
colorectal cancer, non-small cell lung cancer, papillary renal cell carcinomasource ↗
▲Runway Guidance UpdateCorporate
Expects to end 2026 with $400M-$430M cash and sufficient resources through 2028
◆Full ResultsXmAb942Clinical Data
Present final results from the Phase 1 study of XmAb942 in healthy volunteers
inflammatory bowel disease (healthy volunteers)source ↗
●Preclinical PoCXmAb412Preclinical
Present preclinical characterization of XmAb412
inflammatory bowel diseasesource ↗
▲Quarterly UpdateCorporate
Preliminary cash position and financial guidance: $611M cash, sufficient through 2028
▲Patent GrantedIP / Competition
Issuance of U.S. Patent 12,492,253 covering Xtend Fc domain for anti-C5 antibodies
▲Runway Guidance UpdateCorporate
Cash runway guidance: expects to fund operations through end of 2025
◆Enrollment UpdateXmAb819Trial
Enrolling first Phase 1 dose expansion cohort
advanced clear cell renal cell carcinomasource ↗
▲Topline ReadoutXmAb819Clinical Data
Initial results from ongoing dose-escalation study presented
advanced clear cell renal cell carcinomasource ↗
◆Trial InitiationXmAb657Trial
Phase 1 study of XmAb657 to initiate in 4Q 2025
autoimmune diseasessource ↗
▲Oral PresentationXmAb819Presentation
Initial results from Phase 1 dose-escalation study of XmAb819 presented at AACR-NCI-EORTC Conference
advanced clear cell renal cell carcinomasource ↗
▲Oral PresentationXmAb541Presentation
Early efficacy data from Phase 1 dose-escalation study of XmAb541 presented
advanced gynecologic and germ cell tumorssource ↗
▲Oral PresentationASP2138Presentation
First clinical data from Astellas' ASP2138 presented at ESMO congress
gastric, gastroesophageal junction and pancreatic cancerssource ↗
▲Primary Endpoint MetobexelimabClinical Data
Positive results from Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis; primary endpoint met
relapsing multiple sclerosissource ↗
▲Trial InitiationXmAb942Trial
Initiated Phase 2b XENITH-UC study of XmAb942 in ulcerative colitis
ulcerative colitissource ↗
Past FDA Catalysts and PDUFA Decisions
How XNCR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-25 | XmAb819 | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
13
Drugs Scored
rNPV / MCap
Top Drug
Top 20%
Micro Cap(rank 132 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Plamotamab Monoclonal antibodyNCT07230353 | Rheumatoid Arthritis | Phase 1 | RECRUITING | 68 | Jun 1, 2028 | ||||||
| vudalimab Monoclonal antibodyNCT05032040 | Ovarian Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 170 | Dec 30, 2025 | ||||||
| XmAb942 Monoclonal antibodyNCT06619990 | Ulcerative Colitis (UC) | Phase 1 | RECRUITING | 270 | May 1, 2030 | ||||||
| XmAb541 Monoclonal antibodyNCT06276491 | Ovarian Cancer | Phase 1 | RECRUITING | 372 | Dec 1, 2028 | ||||||
| XmAb819 Monoclonal antibodyNCT05433142 | Clear Cell Renal Cell Carcinoma | Phase 1 | RECRUITING | 307 | Dec 1, 2028 | ||||||
| XmAb412 Monoclonal antibodyNCT07713485 | Not Applicable - Healthy Adult Participants | Phase 1 | RECRUITING | 128 | Mar 1, 2028 | ||||||
| XmAb657 Monoclonal antibodyNCT07284797 | Idiopathic Inflammatory Myopathies | Phase 1 | RECRUITING | 60 | Oct 1, 2028 | ||||||
| XmAb13676 Monoclonal antibodyCompletedNCT02924402 | B-cell Non-Hodgkins Lymphoma | Phase 1 | COMPLETED | 154 | Apr 1, 2024 | ||||||
| vudalimab Monoclonal antibodyCompletedNCT05005728 | Metastatic Castration-Resistant Prostate Cancer | Phase 2 | COMPLETED | 72 | Jun 10, 2025 | ||||||
| XmAb22841 Monoclonal antibodyCompletedNCT03849469 | Melanoma | Phase 1 | COMPLETED | 78 | Feb 16, 2023 | ||||||
| XmAb23104 Monoclonal antibodyCompletedNCT03752398 | Melanoma (Excluding Uveal Melanoma) | Phase 1 | COMPLETED | 198 | Feb 15, 2024 | ||||||
| XmAb20717 Monoclonal antibodyCompletedNCT03517488 | Melanoma | Phase 1 | COMPLETED | 150 | Sep 6, 2022 | ||||||
| XmAb808 Monoclonal antibodyCompletedNCT05585034 | Head and Neck Squamous Cell Carcinoma | Phase 1 | COMPLETED | 60 | May 20, 2025 | ||||||
| XmAb18087 Monoclonal antibodyCompletedNCT03411915 | Neuroendocrine Tumor | Phase 1 | COMPLETED | 62 | Oct 26, 2021 | ||||||
| XmAb27564 Small moleculeCompletedNCT04857866 | Undisclosed | Phase 1 | COMPLETED | 48 | Nov 10, 2022 | ||||||
| XmAb5871 Monoclonal antibodyCompletedNCT02725476 | IgG4-RD | Phase 2 | COMPLETED | 20 | Dec 1, 2017 | ||||||
| XmAb5574 Monoclonal antibodyMarketedNCT01161511 | Chronic Lymphocytic Leukemia | Phase 1 | COMPLETED | 27 | Jan 1, 2013 |
Clinical Trial Results
Readouts, endpoints and source filings for every XNCR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| XmAb819 | advanced clear cell renal cell carcinoma | Phase 1 | 2026-10-25 | confirmed objective response rate: 45.5%; unconfirmed objective response rate: 55%; six month progression free survival: 82%Read More | Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ TumorsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Feigal EllenDirector | Sell | -6,843 12,340 held | $13.06 | 06/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XNCR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 2.9 % (7.4 %) | 114.85 M | 7.13 M |
XNCR Institutional Ownership Trends
XNCR Short Interest
Shares sold short, counted twice a month.
23.39%
Short % of Float
of tradable shares sold short
16.4M
Shares Sold Short
+3.9% vs prior count
10.1 Very high
Days to Cover
trading days of normal volume to buy every short share back
1.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XNCR ranks across every disease it competes in
Competitive Position is a premium feature
See how XNCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXNCR News
XNCR▼ -2.5%today
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
Xencor presented Phase 1 results for XmAb819 at ESMO 2026, showing a 45.5% confirmed objective response rate in advanced clear cell renal cell carcinoma patients. The company proposes a 400 mcg/kg dose for Phase 3 trials and plans to discuss accelerated approval with the FDA. XmAb819 demonstrates a unique mechanism as a potential first-in-class treatment.
Read more →XNCRXencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. will host a webcast on October 26, 2026, to discuss the results of its Phase 1 study of XmAb819, a bispecific antibody for advanced clear cell renal cell carcinoma. The study results will also be presented at the ESMO Congress 2026 in Madrid. XmAb819 is designed to engage T cells for targeted tumor cell destruction.
Read more →XNCRXencor to Present at the 2026 Cantor Global Healthcare Conference
Xencor, Inc. has announced its participation in the Cantor Global Healthcare Conference scheduled for September 9, 2026. The presentation will be made by company management at 10:55 a.m. EDT. A live webcast will be available on Xencor's website, with a replay accessible for 30 days post-event.
Read more →XNCRXencor Reports Second Quarter 2026 Financial Results
Xencor, Inc. has reported its financial results for the second quarter of 2026. The company is focused on developing engineered antibodies for cancer and autoimmune diseases. CEO Bassil Dahiyat expressed enthusiasm for presenting XmAb819 results at the upcoming ESMO event and highlighted key milestones in their clinical pipeline.
Read more →XNCR▲ +10%on this news
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
Xencor, Inc. has reached a settlement with Alexion Pharma to resolve a dispute over U.S. royalties related to Ultomiris. As part of the agreement, Xencor will receive $105 million. This resolution is expected to enhance Xencor's financial stability and eliminate uncertainties regarding royalty payments.
Read more →XNCR▲ +16.9%on this news· ran to +31% by day 3
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. has announced that results from its Phase 1 clinical study of XmAb819, a bispecific antibody targeting advanced clear cell renal cell carcinoma, will be presented at the ESMO Congress 2026. This presentation highlights the potential of XmAb819 in cancer treatment and underscores Xencor's commitment to developing innovative therapies.
Read more →XNCRXencor Reports First Quarter 2026 Financial Results
Xencor has reported its financial results for the first quarter of 2026. The article does not provide specific details about the financial performance or any significant developments during this period. Further insights into the company's operations or future outlook are not mentioned.
Read more →XNCRxncr-20260504xexx991 Designing Proteins Delivering Medicines Results from Phase 1 Study of XmAb942 & TL1A Pipeline Update
Xencor has reported positive results from its Phase 1 study of XmAb942, a drug targeting TL1A for inflammatory bowel disease. The company highlighted its strong financial foundation and innovative protein engineering capabilities during a recent presentation. XmAb942 is part of a broader portfolio aimed at addressing conditions such as ulcerative colitis. Despite the optimistic results, Xencor acknowledged potential risks related to development timelines and dependence on third parties.
Read more →XNCR▲ +5.3%on this newsshared move
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
Xencor is set to host a webcast to discuss data presentations for XmAb942 and XmAb412 at the upcoming Digestive Disease Week (DDW). This event will provide insights into the latest findings related to these compounds. Further details about the webcast and its content were not disclosed.
Read more →XNCR▼ -12.4%on this news
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
Xencor, Inc. announced that Alexion Pharmaceuticals has stated it will not pay additional royalties for Ultomiris sales in the U.S. while continuing payments for international sales. This dispute has led Xencor to adjust its financial guidance, projecting sufficient cash resources into mid-2028 despite the uncertainty regarding U.S. royalties. The company remains focused on resolving the matter with the Licensee.
Read more →XNCR▲ +13.1%on this news
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
Xencor reported its financial results for Q4 and the full year 2025, highlighting the progress of its clinical pipeline, particularly XmAb819 for ccRCC. The company is on track to present data supporting a Phase 3 dose in 2026 and has opened new cohorts for other cancers. Despite a net loss, revenue increased due to licensing agreements, and cash reserves remain strong.
Read more →XNCRXencor to Participate at Upcoming March 2026 Investor Conferences
Xencor, Inc. has announced its participation in several investor conferences scheduled for March 2026. The company, which focuses on developing engineered antibodies for cancer and autoimmune diseases, will provide live webcasts of the presentations. Replays will be available on their website for 30 days post-event.
Read more →XNCR▼ -5.1%on this news
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
Xencor, Inc., a clinical-stage biopharmaceutical company, has outlined its corporate priorities and key pipeline advancements for 2026, focusing on its XmAb drug candidates for cancer and autoimmune diseases. They plan to initiate pivotal studies and first-in-human trials for several innovative therapies, including bispecific antibodies targeting important inflammatory pathways. Recent clinical data from its XmAb819 candidate shows promise in advanced renal cell carcinoma, contributing to a robust development strategy supported by a strong financial position expected to last through 2028. The company anticipates presenting important updates and milestones across their clinical programs in the coming year.
Read more →XNCRXencor Reports Third Quarter 2025 Financial Results PASADENA, Calif.
Xencor, Inc. reported its financial results for Q3 2025, highlighting advancements in its bispecific antibodies, XmAb819 and XmAb541, which are in Phase 1 studies for cancer treatment. Both candidates showed encouraging clinical data, and Xencor expects to initiate pivotal studies in 2027. Additionally, the company is progressing in its autoimmune portfolio, with patient dosing underway for XmAb942 and plamotamab. Xencor's financial health appears robust, with expectations to sustain operations into 2028.
Read more →XNCR▲ +7.1%on this news· ran to +19% by day 3
xncr-2025x1024xexx991 Initial Results from Ongoing Dose-Escalation Study of XmAb819 & Oncology Pipeline Update
Xencor has released initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a T-cell engager targeting ENPP3 for advanced clear cell renal cell carcinoma. The trial demonstrates promising early signs of efficacy and safety with administered doses. Additionally, the pharmacokinetic data suggest that the drug may support a more convenient dosing schedule. While there are optimistic findings, it is important to consider the risks involved, particularly the heavily pre-treated nature of the patient population. Xencor continues to advance its oncology pipeline, highlighting its ongoing commitment to innovative cancer therapies.
Read more →XNCR▼ -5.8%on this news
Xencor Reports Second Quarter 2025 Financial Results PASADENA, Calif.
Xencor, Inc. has reported its financial results for the second quarter of 2025, showing a significant revenue increase to $43.6 million. The company is advancing multiple clinical studies with promising drug candidates such as XmAb819 and XmAb942 in the oncology and autoimmune disease spaces. Despite the positive growth, Xencor faced a net loss of $30.8 million, although this represents an improvement from the previous year's loss. The firm continues to invest heavily in R&D while preparing for upcoming pivotal trials.
Read more →XNCRXencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
Xencor, Inc. has appointed Raymond J. Deshaies, Ph.D., to its board of directors, bringing over 25 years of experience in biotechnology. Dr. Deshaies has a notable background, having recently served as senior vice president of global research at Amgen, where he oversaw numerous successful clinical candidates. His expertise in drug development and scientific insights is expected to enhance Xencor's advancements in engineered antibodies targeting cancer and autoimmune diseases.
Read more →XNCR▼ -5.6%on this news
Xencor Reports First Quarter 2025 Financial Results -- Recent interim Phase 1 study results for XmAb942 (Xtend anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in participants with
Xencor, Inc. reported its financial results for the first quarter of 2025, highlighting promising interim results for its investigational drug XmAb942, which supports a 12-week maintenance dosing regimen for ulcerative colitis. The company is poised to initiate a Phase 2b study, named XENITH-UC, in the latter half of 2025. Additionally, Xencor announced personnel changes as Nancy Valente transitions from Chief Development Officer to a senior advisory role. The firm has also provided guidance for its financial outlook and expects to maintain sufficient cash flow into 2028.
Read more →XNCRInterim Results from First-in-Human Study of XmAb942 & TL1A Pipeline Update April 29, 2025
Xencor recently provided interim results from the first-in-human study of XmAb942, an antibody designed for treating inflammatory bowel disease (IBD). The company is also advancing multiple clinical candidates, including various bispecific T-cell engagers targeting cancer and autoimmune conditions. XmAb942 is characterized by an extended half-life, aiming to enhance patient compliance with its convenient dosing schedule. However, Xencor acknowledges the inherent risks associated with moving forward in clinical development timelines.
Read more →XNCRXencor Appoints Todd Simpson to Board of Directors PASADENA, Calif.
Xencor, Inc. has appointed Todd Simpson to its board of directors. Simpson, a seasoned financial executive with over 40 years of experience, previously served as CFO at Seagen Inc. where he was instrumental in the launch of multiple oncology medicines. His extensive background in corporate finance and strategic planning is expected to benefit Xencor as it continues to develop engineered antibodies for cancer and autoimmune diseases.
Read more →About Xencor, Inc.
Headquarters465 N. HALSTEAD ST., PASADENA, CA, 91107
BIOPHARMAWATCH ELITE PLUS
Trade the next XNCR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime